Imbalanced Kynurenine Pathway in Schizophrenia

• Published in: International Journal of Tryptophan Research 2014, Vol.2014 (2014), p.15-22
• Main Authors: Kegel, Magdalena E., Bhat, Maria, Skogh, Elisabeth, Samuelsson, Martin, Lundberg, Kristina, Dahl, Marja-Liisa, Sellgren, Carl, Schwieler, Lilly, Engberg, Göran, Schuppe-Koistinen, Ina, Erhardt, Sophie
• Format: Article
• Language: English
• Subjects: Medicin och hälsovetenskap; Neural circuitry; Neurotransmitters; Observations; Original Research; Physiological aspects; Properties; Schizophrenia
• ISSN: 1178-6469; 1178-6469
• DOI: 10.4137/IJTR.S16800

Several studies suggest a role for kynurenic acid (KYNA) in the pathophysiology of schizophrenia. It has been proposed that increased brain KYNA levels in schizophrenia result from a pathological shift in the kynurenine pathway toward enhanced KYNA formation, away from the other branch of the pathway leading to quinolinic acid (QUIN). Here we investigate the levels of QUIN in cerebrospinal fluid (CSF) of patients with schizophrenia and healthy controls, and relate those to CSF levels of KYNA and other kynurenine metabolites from the same individuals. CSF QUIN levels from stable outpatients treated with olanzapine (n = 22) and those of controls (n = 26) were analyzed using liquid chromatography-mass spectrometry. No difference in CSF QUIN levels between patients and controls was observed (20.6 ± 1.5 nM vs. 18.2 ± 1.1 nM, P = 0.36). CSF QUIN was positively correlated to CSF kynurenine and CSF KYNA in patients but not in controls. The CSF QUIN/KYNA ratio was lower in patients than in controls (P = 0.027). In summary, the present study offers support for an over-activated and imbalanced kynurenine pathway, favoring the production of KYNA over QUIN in patients with schizophrenia.